CIPLA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,357 INR | -4.05% |
|
-4.64% | +8.91% |
| 05:19pm | Promoter group to sell stake worth $316 million in India's Cipla, CNBC-TV18 reports | RE |
| 01:08pm | Indian Equities Close Higher on Tuesday, Led by Auto, Metal Stocks | MT |
| Sales 2024 | 258B 3.09B 245B | Sales 2025 * | 280B 3.36B 267B | Capitalization | 1,096B 13.13B 1,043B |
|---|---|---|---|---|---|
| Net income 2024 | 41.22B 494M 39.23B | Net income 2025 * | 46.45B 557M 44.21B | EV / Sales 2024 | 4.69 x |
| Net cash position 2024 * | 55.83B 669M 53.14B | Net cash position 2025 * | 45.26B 542M 43.08B | EV / Sales 2025 * | 3.75 x |
| P/E ratio 2024 |
29.3
x | P/E ratio 2025 * |
23.6
x | Employees | 32,323 |
| Yield 2024 * |
0.62% | Yield 2025 * |
0.7% | Free-Float | 64.49% |
More Fundamentals
* Assessed data
More news
Latest transcript on Cipla Limited
More recommendations
More press releases
More news
| 1 day | -4.05% | ||
| 1 week | -4.64% | ||
| Current month | -3.05% | ||
| 1 month | -2.82% | ||
| 3 months | -6.89% | ||
| 6 months | +9.42% | ||
| Current year | +8.91% |
1 week
1 317.25
1 425.95
1 month
1 317.251 434.00
Current year
1 252.101 519.00
1 year
896.851 519.00
3 years
850.001 519.00
5 years
355.301 519.00
10 years
355.301 519.00
| Managers | Title | Age | Since |
|---|---|---|---|
Umang Vohra
CEO | Chief Executive Officer | 52 | 30/09/15 |
Ashish Adukia
DFI | Director of Finance/CFO | - | 15/08/22 |
Geena Malhotra
CTO | Chief Tech/Sci/R&D Officer | - | 31/12/85 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ashok K. Sinha
BRD | Director/Board Member | 72 | 15/07/13 |
| Chairman | 87 | 21/07/72 | |
| Director/Board Member | 83 | 15/08/77 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.99% | 6 M€ | +6.07% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 14/05/24 | 1,357 | -4.05% | 3 721 994 |
| 13/05/24 | 1,415 | +5.61% | 7,910,590 |
| 10/05/24 | 1,340 | -1.42% | 5,080,539 |
| 09/05/24 | 1,359 | -1.87% | 1,152,636 |
| 08/05/24 | 1,385 | -0.18% | 1,497,782 |
Delayed Quote NSE India S.E., May 14, 2024 at 12:49 pm
More quotes
Cipla specializes in development, manufacturing and marketing of pharmaceutical products. The group provides prescription products and OTC medicines for the treatment of cardiovascular, ophthalmic and dermatological diseases, respiratory troubles, cancers, allergies, infections etc. Besides, Cipla develops and sells veterinary products.
Net sales by source of income break down between sale of products (96.9%) and services (3.1%).
Net sales are distributed geographically as follows: India (39.4%), the United States (18.5%), South Africa (17%) and other (25.1%).
Sector
Pharmaceuticals
Calendar
14/05/2024
- Non-Deal Roadshow
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
33
Last Close Price
1,357
INR
Average target price
1,468
INR
Spread / Average Target
+8.17%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +8.91% | 13.68B | |
| +22.69% | 43.81B | |
| +25.56% | 23.01B | |
| +18.00% | 15.27B | |
| +42.72% | 11.96B | |
| -7.49% | 6.98B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +13.26% | 5.59B | |
| +10.29% | 4.92B |
- Stock Market
- Equities
- CIPLA Stock
